The hydrogels composed of decamethylcucurbit[5]uril (Me Q[5]) and para-phenylenediamine (p-PDA) are first reported herein. They are the first Q[5]-based supramolecular hydrogels, the formation of which is driven by portal exclusion between Me Q[5] and p-PDA. The composition, structure, and properties of the Me Q[5]/p-PDA-based hydrogels are investigated by various techniques. Since the 1D supramolecular chain forms via portal exclusion between Me Q[5] and p-PDA is the key to the formation of the hydrogels, any competitive species, such as metal ions, organic molecules, and amino acids, which can affect the portal exclusion, can change the behavior of the Me Q[5]/p-PDA-based hydrogels. Hence, the hydrogels can be used for various applications. Importantly, the results may provide a new research direction for the preparation of Q[n]-based hydrogels via portal exclusion of Q[n]s with guests.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/marc.202100431 | DOI Listing |
Hepatobiliary Pancreat Dis Int
December 2024
Department of Hepatobiliary and Pancreas Surgery, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China. Electronic address:
Vet Parasitol
January 2025
Department of Veterinary Clinic and Surgery, Veterinary School, Federal University of Minas Gerais - UFMG, Belo Horizonte, Minas Gerais, Brazil; National Institute of Science and Technology in NanoBiopharmaceutics (INCT-Nanobiofar), Belo Horizonte, Minas Gerais, Brazil.
Cardiovascular involvement in Leishmania sp. infections still requires further elucidation, with cutaneous and organic changes being more frequently observed. The aim of this study was to conduct a systematic review of cardiovascular involvement in dogs with canine visceral leishmaniasis, considering a publication span of over 80 years.
View Article and Find Full Text PDFIntroduction: Atezolizumab plus bevacizumab significantly improved overall survival (OS) and progression-free survival (PFS) versus sorafenib in patients with unresectable hepatocellular carcinoma (HCC) in IMbrave150. Efficacy and safety in patient subpopulations with Vp4 portal vein tumor thrombosis (PVTT) and other high-risk prognostic factors are reported.
Methods: IMbrave150 was a global, randomized (2:1), open-label, phase 3 study in systemic treatment-naive patients with unresectable HCC; OS and PFS were co-primary endpoints.
J Stroke Cerebrovasc Dis
January 2025
Hospital Universitário Clementino Fraga Filho, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil; D'Or Institute for Research and Education, Rio de Janeiro, Brazil. Electronic address:
Eur Phys J C Part Fields
November 2024
ETH Zürich, Institute for Particle Physics and Astrophysics, 8093 Zurich, Switzerland.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!